Editorial: Immunotherapy resistance and advancing adaptive cell therapeutics

Editorial: Immunotherapy resistance and advancing adaptive cell therapeutics

Saved in:

Bibliographic Details
Main Authors:	Luciana Rodrigues Carvalho Barros, Amar Yeware
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Immunology
Subjects:	oncoimmunology adaptive cell therapy chimeric antigen receptor (CAR) immunotherapy resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1640317/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
by: Mingwei Jiang, et al.
Published: (2025-12-01)

CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia
by: E. V. Glukhanyuk, et al.
Published: (2019-01-01)

Editorial: Innovative immunotherapy strategies for enhanced treatment of Hodgkin and non-Hodgkin lymphomas
by: Michael J. Robertson, et al.
Published: (2025-06-01)

Study of the suppression of a tumor growth expressing a carcinoembryonic antigen with a new high-tech drug carplasmin (CAR-T therapy) in Balb/c nude mice
by: V. K. Bozhenko, et al.
Published: (2023-04-01)

Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects
by: Hongzhuo Qin, et al.
Published: (2025-06-01)

Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies
by: Xiaoshuang Yuan, et al.
Published: (2025-05-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Nano-immunotherapy for lung cancer
by: Yuting Lu, et al.
Published: (2023-03-01)

Direct visualization of chimeric antigen receptors on primary human T cells using dSTORM super-resolution microscopy
by: Leon Gehrke, et al.
Published: (2025-08-01)

Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases
by: Alejandrina Hernández-López, et al.
Published: (2025-01-01)

CAR-T: from bench to bedside
by: M. О. Popova, et al.
Published: (2024-09-01)

Chimeric Autoantibody Receptor- and/or Peptide-MHC-Based CAR Therapies for Targeted Elimination of Antigen-Specific B or T Cells in Hypersensitivity Disorders Such as Allergies and Autoimmune Diseases
by: Isidora Protić-Rosić, et al.
Published: (2025-05-01)

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology
by: Alina Ershova, et al.
Published: (2025-07-01)

Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review
by: Ahsen Morva, et al.
Published: (2025-06-01)

Tandem CAR-T cell therapy: recent advances and current challenges
by: Sara Gómez-Melero, et al.
Published: (2025-02-01)

γδT cells, a key subset of T cell for cancer immunotherapy
by: Jianzhen Lv, et al.
Published: (2025-03-01)

CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy
by: Filipa D. dos Reis, et al.
Published: (2025-05-01)

An integral membrane constitutively active heparanase enhances the tumor infiltration capability of NK cells
by: Sofia Liborio-Ramos, et al.
Published: (2025-12-01)

A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes—a brief review
by: María Fernanda Segovia, et al.
Published: (2025-03-01)

CAR-T Cell Therapy in Gastrointestinal Cancer, Head and Neck Cancer, and Autoimmune Diseases: Current Advances and Future Perspectives
by: Martyna Kania, et al.
Published: (2025-05-01)

Engineered bacteria assist CAR-cell immunotherapy
by: Tianyu Shao, et al.
Published: (2025-03-01)

From lab to lifesaver: the rise of CAR T-cell therapy in oncology
by: Shriyash S. Jangavali, et al.
Published: (2025-05-01)

Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications
by: Lorraine Pinot, et al.
Published: (2025-06-01)

REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY
by: I. L. Tsarev, et al.
Published: (2017-09-01)

Therapeutic landscape of ovarian cancer: recent advances and emerging therapies
by: Ling Wang, et al.
Published: (2025-08-01)

Does a natural killer need a CAR?
by: Kangbo Wang, et al.
Published: (2025-06-01)

Checkmate awaiting strategy: unlocking the potential of chimeric antigen receptor T-cell therapy in uveal melanoma
by: Ahmed H. Al Sharie, et al.
Published: (2025-02-01)

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
by: Gohar S. Manzar, et al.
Published: (2025-01-01)

Natural killer cell-based cancer immunotherapy: from basics to clinical trials
by: Yinghong Shi, et al.
Published: (2024-10-01)

The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer
by: Hao-Yu Tang, et al.
Published: (2025-01-01)

CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases
by: Yuanhao Wu, et al.
Published: (2025-08-01)

New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
by: Yuanyuan Yang, et al.
Published: (2024-11-01)

CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges
by: Yexin Zhou, et al.
Published: (2024-11-01)

Interplay between cancer-associated fibroblasts and dendritic cells: implications for tumor immunity
by: Fátima María Mentucci, et al.
Published: (2025-05-01)

Approved CAR-T therapies have reproducible efficacy and safety in clinical practice
by: Daniel Goyco Vera, et al.
Published: (2024-12-01)

Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy
by: Ali Moazzeni, et al.
Published: (2025-04-01)

Autotransplantation of T-lymphocytes as a tool for antigen-specific immunotherapy of oncological diseases
by: A. Yu. Lupatov, et al.
Published: (2018-09-01)

Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation
by: Catrin Heim, et al.
Published: (2024-06-01)

Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01)

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22
by: Scott McComb, et al.
Published: (2024-03-01)